EU HTA Regulation and Joint Clinical Assessment-Threat or Opportunity?
The vision of a unified European HTA is by no means a new endeavor. At its core are the publicly declared ambitions to harmonize assessments of clinical data within the EU and avoid the duplication of efforts. Not surprisingly, these ambitions are publicly announced to be motivating the new 2022 EU...
Saved in:
Main Author: | Volker Schuster (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?
by: Alejandra Castanon, et al.
Published: (2024) -
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators
by: Thomas Desmet, et al.
Published: (2024) -
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy
by: Francine Brinkhuis, et al.
Published: (2024) -
Implementing the EU HTA regulation: Insights from semi-structured interviews on patient expectations, Belgian and European institutional perspectives, and industry outlooks
by: Thomas Desmet, et al.
Published: (2024) -
A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
by: Nicola Allen, et al.
Published: (2017)